Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) EPS (Basic) (2016 - 2026)

Ovid Therapeutics filings provide 11 years of EPS (Basic) readings, the most recent being -$0.12 for Q1 2026.

  • Quarterly EPS (Basic) rose 14.29% to -$0.12 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $205.88 through Mar 2026, up 75.07% year-over-year, with the annual reading at -$0.23 for FY2025, 37.84% up from the prior year.
  • EPS (Basic) hit -$0.12 in Q1 2026 for Ovid Therapeutics, down from $374.07 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $374.07 in Q4 2025 and bottomed at -$168.01 in Q3 2025.
  • Average EPS (Basic) over 5 years is $9.38, with a median of -$0.17 recorded in 2022.
  • The largest annual shift saw EPS (Basic) tumbled 85426.32% in 2024 before it skyrocketed 287846.15% in 2025.
  • Ovid Therapeutics' EPS (Basic) stood at -$0.16 in 2022, then plummeted by 31.25% to -$0.21 in 2023, then skyrocketed by 38.1% to -$0.13 in 2024, then skyrocketed by 287846.15% to $374.07 in 2025, then plummeted by 100.03% to -$0.12 in 2026.
  • Per Business Quant, the three most recent readings for OVID's EPS (Basic) are -$0.12 (Q1 2026), $374.07 (Q4 2025), and -$168.01 (Q3 2025).